As our understanding of the control of vasculogenesis and angiogenesis continues to grow, we will be confronted with an increasing number of interacting and intersecting receptor-mediated signaling pathways. If we are to be successful in developing new and novel effective therapeutic reagents that can function as stimulators or inhibitors of these critically important processes, we will have to develop a sophisticated, full understanding of the complex interactions associated with ephrin-based and metalloprotease-based signaling pathways.